Experimental drug ACT001 targets tough brain tumors in small trial
NCT ID NCT06894225
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing an oral drug called ACT001 in 12 adults whose glioblastoma has returned after standard treatment. The study focuses on patients whose tumors have a specific genetic signature (STAT3-high). Researchers will check if the drug can shrink or stabilize the tumor for at least 24 weeks. The trial is currently suspended.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ACT001 (a drug taken orally twice daily)
- What this could lead to
- If successful, this could point toward a new treatment option for patients with recurrent glioblastoma who have a specific genetic marker.
- What could go wrong
- This is a very small, early-phase trial with only 12 participants, and it is currently suspended. The drug may not shrink tumors or improve survival, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Neuroscience Institute
Singapore, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a modified herpes virus fight recurrent brain tumors?
- Can a new pill take on brain cancer?
- Can a special MRI reveal hidden brain tumors and guide a stronger radiation strike?
- Radioactive beads take aim at brain tumours
- Two-Drug combo aims to outsmart recurrent brain tumors